Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 17,303 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of the company’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $27.97, for a total transaction of $483,964.91. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at $5,415,019.97. This represents a 8.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Chi also recently made the following trade(s):

• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.00, for a total value of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00.

Hims & Hers Health Trading Down 6.8 %

NYSE:HIMS opened at $26.56 on Monday. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02. The company has a market cap of $5.80 billion, a PE ratio of 60.37 and a beta of 1.25. The company’s 50 day moving average is $26.37 and its two-hundred day moving average is $21.47.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.04) earnings per share. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Morgan Stanley began coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target on the stock. Piper Sandler restated a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Finally, TD Cowen reiterated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $22.80.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HIMS. Main Management ETF Advisors LLC purchased a new stake in Hims & Hers Health in the third quarter valued at approximately $672,000. Robeco Institutional Asset Management B.V. acquired a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $604,000. Carnegie Investment Counsel purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $5,531,000. Royce & Associates LP increased its stake in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares during the period. Finally, Versor Investments LP purchased a new position in shares of Hims & Hers Health during the third quarter worth $634,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.